Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | ACACB | O00763 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887222 | 1.00 | TACR1 (0.53) | TACR1HDAC1HDAC6ACACBCYP1A2 | |
| SCHEMBL5887220 | 1.00 | TACR1 (0.53) | TACR1HDAC1HDAC6ACACBCYP1A2 | |
| SCHEMBL502911 | 0.88 | HDAC1 (0.65) | TACR1HDAC1HDAC6ACACBCYP1A2 | |
| SCHEMBL5887330 | 0.88 | HDAC1 (0.65) | TACR1HDAC1HDAC6ACACBCYP1A2 | |
| SCHEMBL12453492 | 0.88 | TACR1 (0.59) | TACR1ACACBTP53ALDH1A1CTSS | |
| SCHEMBL25669503 | 0.88 | TACR1 (0.59) | TACR1ACACBTP53ALDH1A1CTSS | |
| Acetyl Tyrosine Ethyl Ester SCHEMBL14370511 | 0.87 | TACR1 (0.58) | TACR1MMEACE | |
| Acetyl Tyrosine Ethyl Ester SCHEMBL468756 | 0.87 | TACR1 (0.58) | TACR1MMEACE | |
| Acetyl Tyrosine Ethyl Ester SCHEMBL468858 | 0.87 | TACR1 (0.58) | TACR1MMEACE | |
| Acetyl Tyrosine Ethyl Ester SCHEMBL25257912 | 0.85 | TACR1 (0.56) | TACR1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| CN-1160368-C | Endothelin antegon | 中国人民解放军军事医学科学院毒物药 | 2004-08-04 | — | — | CN | disclosed |
| CN-1155611-C | Endothelin antagon | 中国人民解放军军事医学科学院毒物药 | 2004-06-30 | — | — | CN | disclosed |
| CN-1155612-C | Endothelin antagon | 中国人民解放军军事医学科学院毒物药 | 2004-06-30 | — | — | CN | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| CN-1330075-A | Endothelin antagon | INST OF TOXIC MEDICINES PLA S (CN) | 2002-01-09 | — | — | CN | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | TACR1 509/4885HDAC1 374/4885HDAC6 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.